The One-carbon Therapeutics team is proud and excited to share our latest paper published in
Nature Metabolism describing the detailed mode of action of our potent MTHFD1/2 inhibitor
TH9619 under development for difficult-to-treat cancers. It explains the inhibitor’s cancer specificity
and emphasises the importance of utilising correct human-like conditions and cancer models in drug
development. We show that cancer-specific formate overflow drives toxic folate trapping upon
inhibition of cytosolic MTHFD1, leading to cancer cell death.
One-carbon Therapeutics AB announces the addition of multiple international experts to its Scientific Advisory Board
Professor Johann de Bono, Head of the Division of Clinical